Erythropoiesis

Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease

Retrieved on: 
火曜日, 8月 10, 2021
IND, Birmingham, Patient, A Call for Unity, Sickle cell disease, Adult, Fetal hemoglobin, Kinetics, PRC2, Clinical trial, Half-life, Program, Monocyte, Nasdaq, Safety, SCD, HBG, Biology, HBF, Hemoglobinopathy, Investigational New Drug, RNA transfection, H3K27me3, PD, EED, Pharmacokinetics, GLOBE, Volunteering, University, SAD, Thalassemia, MAD, Lysine, Erythropoiesis, Therapy, Pharmaceutical industry, Vaccine

The increases in F-reticulocytes indicate that the HBG mRNA increases observed with FTX-6058 treatment are translating to HbF protein production.

Key Points: 
  • The increases in F-reticulocytes indicate that the HBG mRNA increases observed with FTX-6058 treatment are translating to HbF protein production.
  • These results with FTX-6058 are very encouraging, said Julie Kanter, MD, co-director, Lifespan Comprehensive Sickle Cell Center at the University of Alabama at Birmingham.
  • We look forward to moving this program forward into a trial in people living with sickle cell disease in the fourth quarter of 2021.
  • FTX-6058 Phase 1 Healthy Volunteer Trial to Assess Safety, Tolerability, and Pharmacokinetics
    The Phase 1 randomized, double-blind, placebo-controlled trial is designed to evaluate the safety, tolerability, and pharmacokinetics of FTX-6058 ( NCT04586985 ).

Disc Medicine to Present at the Piper Sandler 32nd Annual Healthcare Conference

Retrieved on: 
月曜日, 11月 23, 2020
Branches of biology, Anatomy, Hepatology, Hepcidin, Iron metabolism, Erythropoiesis, Hematology

CAMBRIDGE, Mass., Nov. 23, 2020 /PRNewswire/ --Disc Medicine, a hematology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating diseases, announced it will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 23, 2020 /PRNewswire/ --Disc Medicine, a hematology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating diseases, announced it will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference.
  • A pre-recorded presentation by John Quisel, J.D., Ph.D., Chief Executive Officer of Disc Medicine, will be available beginning on Monday, November 23 at 10:00 am Eastern Standard Time.
  • A link to the presentation will be provided in the "News & Events" section of Disc Medicine's website at www.discmedicine.com .
  • Disc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases.

Disc Medicine Expands Scientific Advisory Board with Leading Experts in Hepcidin Biology

Retrieved on: 
火曜日, 10月 13, 2020
Iron metabolism, Blood proteins, Hepatology, Peptide hormones, Hepcidin, Branches of biology, Erythropoiesis, HEPC

"We are thrilled to welcome Dr. Ganz and Dr. Nemeth to our Scientific Advisory Board, particularly at such an exciting time in a field that they helped pioneer," said John Quisel, JD, PhD, Chief Executive Officer at Disc Medicine.

Key Points: 
  • "We are thrilled to welcome Dr. Ganz and Dr. Nemeth to our Scientific Advisory Board, particularly at such an exciting time in a field that they helped pioneer," said John Quisel, JD, PhD, Chief Executive Officer at Disc Medicine.
  • "Disc has taken a compelling approach to targeting hepcidin with two programs guided by human genetic findings.
  • Disc Medicine is developing two separate therapeutic programs focused on modulating hepcidin expression to treat conditions related to iron dysregulation.
  • Disc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases.

Disc Medicine to Present at Citi's 15th Annual BioPharma Virtual Conference

Retrieved on: 
火曜日, 9月 8, 2020
Blood proteins, Hepatology, Iron metabolism, Peptide hormones, Hepcidin, Branches of biology, Erythropoiesis

CAMBRIDGE, Mass., Sept. 8, 2020 /PRNewswire/ -- Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced that John Quisel, J.D., Ph.D., Chief Executive Officer of Disc Medicine, will present at Citi's 15th Annual BioPharma Virtual Conference today, Tuesday, September 8, 2020 at 2:20pm ET.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 8, 2020 /PRNewswire/ -- Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced that John Quisel, J.D., Ph.D., Chief Executive Officer of Disc Medicine, will present at Citi's 15th Annual BioPharma Virtual Conference today, Tuesday, September 8, 2020 at 2:20pm ET.
  • Disc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases.
  • Focused on the hepcidin pathway, the master regulator of iron metabolism, Disc is developing a portfolio of first-in-class therapeutic candidates to transform the treatment of hematologic diseases.
  • View original content to download multimedia: http://www.prnewswire.com/news-releases/disc-medicine-to-present-at-citi...

The Erythropoietin Stimulating Agents Market in Latin America (2019-2027): Data on Epoetin-Alfa, Epoetin-Beta, Epoetin-Theta, Darbepoetin-Alfa, and Other ESAs

Retrieved on: 
水曜日, 11月 27, 2019
Branches of biology, Medicine, Medical specialties, Growth factors, RTT, Cytokines, Erythropoietin, Hematopoiesis, Erythropoiesis-stimulating agent, Erythropoiesis

DUBLIN, Nov. 27, 2019 /PRNewswire/ -- The "Latin America Erythropoietin Stimulating Agents Market Demand Analysis & Opportunity Evaluation, 2019-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 27, 2019 /PRNewswire/ -- The "Latin America Erythropoietin Stimulating Agents Market Demand Analysis & Opportunity Evaluation, 2019-2027" report has been added to ResearchAndMarkets.com's offering.
  • The Latin America erythropoiesis stimulating agents (ESA) market reached USD 319.2 million in 2018 and is expected to reach USD 533.92 million by 2027, by registering a CAGR of 6.03%, across the region.
  • The demand for erythropoiesis stimulating agents is increasing on the back of the rising demand for efficient drugs to control the effects of impaired production of the molecule erythropoietin.
  • Brazil is slated to account for a share of 44.77% and reach USD 239.03 million by 2027 in the erythropoiesis stimulating agents market.

Latin America's $534M Erythropoietin Stimulating Agents Market, 2019-2027: Demand Analysis & Opportunity Evaluation - ResearchAndMarkets.com

Retrieved on: 
火曜日, 11月 26, 2019
Health, Pharmaceutical, Branches of biology, Medicine, Medical specialties, Growth factors, RTT, Erythropoiesis-stimulating agents, Cytokines, Erythropoietin, Erythropoiesis

The "Latin America Erythropoietin Stimulating Agents Market Demand Analysis & Opportunity Evaluation, 2019-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Latin America Erythropoietin Stimulating Agents Market Demand Analysis & Opportunity Evaluation, 2019-2027" report has been added to ResearchAndMarkets.com's offering.
  • The Latin America erythropoiesis stimulating agents (ESA) market reached USD 319.2 million in 2018 and is expected to reach USD 533.92 million by 2027, by registering a CAGR of 6.03%, across the region.
  • The demand for erythropoiesis stimulating agents is increasing on the back of the rising demand for efficient drugs to control the effects of impaired production of the molecule erythropoietin.
  • Brazil is slated to account for a share of 44.77% and reach USD 239.03 million by 2027 in the erythropoiesis stimulating agents market.

Disc Medicine Expands Pipeline Focused on Hepcidin Pathway

Retrieved on: 
火曜日, 10月 29, 2019
Iron metabolism, Medical specialties, Branches of biology, Blood, Blood proteins, Hepatology, Peptide hormones, Hepcidin, Anemias, Hemojuvelin, Erythropoiesis, Human iron metabolism

"The addition of these hemojuvelin antagonist antibodies to our pipeline is an excellent strategic fit for Disc Medicine," said Brian MacDonald, founder and interim CEO of Disc Medicine.

Key Points: 
  • "The addition of these hemojuvelin antagonist antibodies to our pipeline is an excellent strategic fit for Disc Medicine," said Brian MacDonald, founder and interim CEO of Disc Medicine.
  • "Our first program is a novel, orally administered therapy which increases hepcidin expression to treat iron loading anemias.
  • Disc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases.
  • Focused on the hepcidin pathway, the master regulator of iron metabolism, Disc is advancing first-in-class therapies to transform the treatment of hematologic diseases.

Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting

Retrieved on: 
月曜日, 6月 18, 2018
Medicine, Blood, Hematology, Iron metabolism, RTT, Blood proteins, Hepatology, Hepcidin, Beta thalassemia, Anemia, Thalassemia, Erythropoiesis

Protagonist is developing PTG-300 for the treatment of anemia and iron overload in related rare blood disorder diseases, including beta thalassemia.

Key Points: 
  • Protagonist is developing PTG-300 for the treatment of anemia and iron overload in related rare blood disorder diseases, including beta thalassemia.
  • "This observation was evident in both single ascending and repeat doses -- a clear demonstration of pharmacodynamic-based proof-of-concept in human volunteers.
  • We continue to work toward initiation of an open label Phase 2 trial in the fourth quarter of 2018."
  • Agents with hepcidin activity may help correct iron distribution abnormalities and have beneficial effects on erythropoiesis.